Expedited Access to Biosimilars Act
Summary
What This Bill Does
The final Expedited Access to Biosimilars Act revises the evidence required in a biosimilar application. Applicants must provide an appropriate assessment of pharmacokinetics and immunogenicity, which may rely on or consist of clinical pharmacokinetic studies. FDA may require a clinical study assessing pharmacodynamics or efficacy only after a written determination that it is necessary, together with the other evidence, to show no clinically meaningful difference in safety, purity, and potency. FDA must provide the determination with development-meeting minutes or explain why it cannot yet decide, and then decide within 60 days after application. Afterward FDA may add a study only with sponsor agreement or documented scientific justification and a requested meeting. The bill also removes the rule requiring the same FDA division that reviewed the reference product to review the biosimilar.
Who Benefits and How
Biosimilar developers gain earlier certainty and may avoid expensive comparative efficacy or pharmacodynamic trials that FDA cannot specifically justify. Patients, insurers, and purchasers may benefit from lower development barriers and earlier competition. FDA gains flexibility to assign applications outside the reference product's original review division.
Who Bears the Burden and How
FDA biosimilar reviewers must issue timely written determinations, explain delayed decisions, and document any later scientific justification for added studies. Reference biologic manufacturers may face earlier competition, while clinical-research providers may lose work from studies no longer routinely required. Sponsors still bear pharmacokinetic, immunogenicity, and any justified study costs.
Key Provisions
- Limits pharmacodynamic or efficacy studies to cases FDA finds necessary in writing.
- Requires FDA to decide at a development meeting or within 60 days after application.
- Bars later-added studies absent sponsor agreement or detailed scientific justification.
- Removes the same-FDA-division review requirement for biosimilar applications.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Reduces default clinical-study demands for biosimilar applications and requires FDA to justify, time, and constrain case-specific pharmacodynamic or efficacy study requirements.
Key Policy Areas
Healthcare, Drug Regulation, Biotechnology
Primary Purpose
Reduces default clinical-study demands for biosimilar applications and requires FDA to justify, time, and constrain case-specific pharmacodynamic or efficacy study requirements.
Policy Domains
Expedited Access to Biosimilars Act
Identified Gains
- Biosimilar developers
- Patients using biologic medicines
- Health insurers
- FDA application managers
Identified Costs
- FDA biosimilar reviewers
- Reference biologic manufacturers
- Clinical research organizations
- Biosimilar study sponsors
Sponsors
Legislative Progress
ReportedPlaced on Senate Legislative Calendar under General Orders. Calendar No. …
Committee on Health, Education, Labor, and Pensions. Reported by Senator …
Reported by Mr. Cassidy, with an amendment
Committee on Health, Education, Labor, and Pensions. Ordered to be …
Mr. Paul introduced the following bill; which was read twice …
Read twice and referred to the Committee on Health, Education, …
Introduced in Senate
Mr. Paul (for himself, Mr. Lee, and Ms. Hassan) introduced …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Biosimilar developers, Clinical research organizations, Health insurers
Positive-direction: Biosimilar developers, Health insurers
Negative-direction: Clinical research organizations, Reference biologic manufacturers
FDA application managers, FDA biosimilar reviewers, Federal legislative records staff
Positive-direction: FDA application managers
Negative-direction: FDA biosimilar reviewers
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "regulator"
- → Secretary of Health and Human Services acting through FDA
- "applicants"
- → Biosimilar biological product sponsors
- "competitors"
- → Reference biologic manufacturers
- "affected_public"
- → Patients and purchasers of biologic medicines
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology